On November 3, 2022 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an Oral Session at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place on December 10-13, 2022, in New Orleans, Louisiana (Press release, Oncternal Therapeutics, NOV 3, 2022, View Source [SID1234622924]). In the CIRM-0001 study, zilovertamab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and in a recently opened cohort for patients with marginal zone lymphoma (MZL). The clinical trial is being conducted in collaboration with the University of California San Diego (UC San Diego) and has been partially funded by the California Institute for Regenerative Medicine (CIRM).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The interim clinical data has been accepted for an oral presentation during the Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III session on Saturday, December 10, 2022 as part of the ASH (Free ASH Whitepaper) 2022 Annual Meeting. ASH (Free ASH Whitepaper) abstracts were released today, and more recent data updates will be available at the time of the presentation.
Poster Title: Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
Publication Number: 232
Session Name: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III
Room: Ernest N. Morial Convention Center, New Orleans Theater C
Presenter: Hun Ju Lee, MD, Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center
Session Date and Time: December 10, 2022 from 2:00-3:30 pm CST; CIRM-0001 presentation being held at 2:45 pm CST